Haemonetics Corporation
Haemonetics is a U.S.-based medical technology company that designs and sells systems used to collect, process, and manage blood and plasma. Its portfolio spans plasma collection technologies, blood center collection and processing equipment, and hospital products for vascular closure, blood management, and related procedures.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueDevices, disposables, and software used by plasma centers to collect plasma efficiently and manage donor operations.
Collection and processing systems for blood centers handling plasma, red cells, and platelets.
Products used in interventional procedures, including vascular closure, sensor-guided technologies, and esophageal protection.
Products that help hospitals manage bleeding and blood use, including hemostasis, cell salvage, and transfusion management.
Customers
Haemonetics sells primarily to healthcare and blood-collection institutions rather than individual patients. Its main buyers are biopharmaceutical plasma companies, blood collection groups, independent blood centers, hospitals, hospital service providers, group purchasing organizations, and national health organizations. The business is concentrated in a relatively small number of large accounts, especially in Plasma, where customer renewals and pricing decisions can materially affect revenue.
Biopharmaceutical plasma operators buy collection devices, disposables, and software to run donor centers efficiently and reliably.
Independent and institutional blood centers buy collection and processing systems for plasma, red cells, and platelets.
Hospitals buy interventional and blood management products to support procedures, reduce blood loss, and improve workflow.
GPOs influence purchasing decisions and contract access for hospital products.
Public health systems and agencies buy blood collection solutions through tenders and centralized procurement.
Strategy
Haemonetics is prioritizing the Plasma and Hospital segments, which management believes have the strongest growth potential and best long-term value creation. The company is sharpening its focus in Blood Center toward targeted opportunities, especially plasma and platelets, while continuing to invest in internal development and selective inorganic growth. Capital allocation also includes share repurchases to offset equity dilution and support shareholder returns.
Management sees these as the highest-growth businesses and the main drivers of long-term value.
Blood Center operates in more challenging markets, so resources are being concentrated on the most attractive niches.
New products and approvals are needed to defend share and keep pace with clinical and technology changes.
Repurchases and disciplined investment help balance shareholder returns with funding for the business.
Geography
Haemonetics generates most of its revenue in the United States, with the remainder coming from international markets across Europe, Japan, and other parts of Asia. In fiscal 2025, the company reported 74.3% of revenue from the U.S., 12.9% from Europe, 4.6% from Japan, 6.8% from Rest of Asia, and 1.4% from Other markets. The company sells in roughly 95-96 countries and is exposed to foreign exchange movements, especially the yen, euro, and yuan.
Risks
Haemonetics is exposed to customer concentration, especially in Plasma, where a small number of accounts drive a meaningful share of sales and contract renewals can shift quickly. The company also faces regulatory, competitive, and foreign exchange risk because it sells regulated medical products globally and earns a substantial portion of revenue outside the U.S. Accounting and operational results can be affected by demand changes, product approvals, and inventory or rebate estimates.
- Customer concentration and contract non-renewalImpact: HighLikelihood: High
A limited number of Plasma customers account for a material portion of sales, so renewal or pricing changes can quickly affect revenue.
Exposure: Plasma segment
- Regulatory and clinical adoption riskImpact: HighLikelihood: Medium
Products require approvals and must keep pace with evolving clinical practice and standards.
Exposure: All segments
- Competitive pressureImpact: HighLikelihood: Medium
Large global competitors have substantial resources and similar product offerings, which can affect pricing and market share.
Exposure - Foreign exchange volatilityImpact: MediumLikelihood: Medium
International sales are denominated in local currencies, especially yen, euro, and yuan, creating translation and transaction exposure.
Exposure - Cybersecurity and data integrityImpact: MediumLikelihood: Low
Medical devices and software handle sensitive patient and customer information and could be targeted by attackers.
Exposure: Connected products and internal systems
Accounting
Judgemental itemsProduct sales are recorded net of estimated rebates, returns, and discounts, which can shift revenue timing and margins.
Impact: Affects reported sales and gross margin
Forecast errors, product recalls, or delayed approvals can require additional inventory write-downs.
Impact: Affects cost of sales and operating profit
Changes in competition, customer loss, or market size can trigger impairment charges.
Impact: Affects operating income and balance sheet carrying values
The company uses hedges to mitigate exposure to yen, euro, and yuan movements.
Impact: Affects reported earnings and cash flow volatility
Similar listed companies
Publicly listed companies with a comparable business focus.
Xenetic Biosciences, Inc.
XBIO · Pharmaceutical Preparations
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Baxter International Inc
BAX · Surgical & Medical Instruments & Apparatus
HCW Biologics Inc.
HCWB · Pharmaceutical Preparations
Last updated: 24/09/2026